Relmada Therapeutics Inc
RLMD (NASDAQ)
Relmada Therapeutics Inc (RLMD) has garnered significant attention with an impressive one-year return of 2057.72%, despite a slight decline of 1.68% over the past five years. Analysts project a median 12-month price target of $9.00, with a range between $8.00 and $10.00, reflecting a cautiously optimistic outlook. Recent upgrades from firms like Mizuho and Leerink Partners, both rating RLMD as "Outperform," suggest confidence in its future potential.
Pros:
- High one-year return
- Focus on CNS diseases
Cons:
- High risk associated with clinical trials
- Market cap under $500M
Relmada Therapeutics Inc (RLMD) may be suitable for investors with a high-risk tolerance who are seeking exposure to biotech stocks and are encouraged by its substantial recent returns and optimistic analyst ratings. However, potential investors should consider the company's lack of dividend yield and the mixed long-term performance before making a decision.